Mary Beth Harler

MARY BETH HARLER, MD  is head of innovative medicines development with Bristol-Myers Squibb. She previously held the position of head of innovative clinical development in the cardiovascular, fibrosis, immunoscience, and genetically defined diseases (CFIG) group.  Prior to this, Harler was the head of immunoscience clinical development, and the FDT lead for Nulojix. She joined Bristol-Myers Squibb in January 2010 from Pfizer (Wyeth), where she spent nine years in development and medical.  Most recently, Harler was an assistant vice president of inflammation and immunology, responsible for a number of clinical development teams supporting Enbrel, Rapamune, and the immunology pipeline. She trained as a general surgeon at Brown University, where she also served as a research fellow focusing on immune modulation and wound healing. @bmsnews